Share class
Morningstar Rating
Bloomberg Ticker
CR1SEIC SW
NAV
1428.96
23.04.2026
YTD
3.46%
as of 23.04.2026
3M
3.69%
as of 23.04.2026
1Y
14.82%
as of 23.04.2026
Share Class name
Credit Suisse (CH) 130/30 Swiss Equity Fund IB CHF
Overview
The fund targets its investments on equities of companies that are domiciled in Switzerland or are included in the SPI.
Criteria for stock selection include the valuation of the company, the business climate, the company`s positioning and the quality of its management.
The long exposure can go up to 130% and the short exposure to -30%.
Benefits
The aim is to outperform the SPI over the long term. Fluctuations in the value of the fund units may differ substantially from those in the SPI.
Risks
This fund invests in equities and may therefore be subject to high fluctuations in value. As these UBS funds pursue an active management style, each fund's performance can deviate from that of its reference index. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).
Features
| Product category |
UBS Country & Regional Funds / Europe
|
| Product domicile |
Switzerland
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS Fund Management (Switzerland) AG
|
| Custodian bank |
UBS Switzerland AG, Zurich
|
| Day of inception |
June 4, 2020
|
| Currency of account |
CHF
|
| Close of financial year |
May 31
|
| SFDR Classification |
n.a.
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.17% p.a.
|
| Management fee |
0.50% p.a.
|
| Total expense ratio (TER) |
0.58% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
SPI® (TR) in CHF
|
| Securities no. |
54799893
|
| ISIN |
CH0547998937
|
| Bloomberg Ticker |
CR1SEIC SW
|
| Reuters Id |
54799893X.CHE
|
Performance and Prices
Percentage growth
as of April 23, 2026
Cumulative
| CHF(%) | EUR(%) | USD(%) | |
| YTD | 3.46 | 4.89 | 4.59 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 16.14 | 17.13 | 32.85 |
| 3Y | |||
| 5Y | 29.43 | 55.81 | 51.44 |
| ø p.a.5Y | 5.29 | 9.28 | 8.65 |
Current data
| Net asset value | 23.04.2026 | CHF 1,428.96 |
| High - last 12 months | 27.02.2026 | CHF 1,466.39 |
| Low - last 12 months | 25.09.2025 | CHF 1,234.15 |
| Assets of the unit class in mn | 23.04.2026 | CHF 18.10 |
| Total product assets in mn | 23.04.2026 | CHF 267.68 |
Statistical data
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 11.72% | 12.29% |
| Sharpe Ratio | 31.03.2026 | 0.36 | 0.35 |
| Risk Free Rate | 31.03.2026 | 0.46% | 0.40% |
Structures
By the 10 largest positions (in %, as of March 31, 2026)
|
|
|
| Roche Holding AG | 16.02 |
| Nestle SA | 13.42 |
| Novartis AG | 12.76 |
| Zurich Insurance Group AG | 7.56 |
| UBS Group AG | 7.17 |
| ABB Ltd | 6.32 |
| Swiss Re AG | 4.58 |
| Cie Financiere Richemont SA | 3.99 |
| Lonza Group AG | 3.24 |
| Amrize Ltd | 2.98 |
Fees
Performance Fee
15.0000%
Distributions
No distributions. Continuous reinvestment of income.
Sales Authorisations
Literature
Brochures
Agreement / Prospectus
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
|
Annual and semi-annual report (accounting on May 31)
|
Document type
|
Document Language
|
|
| Annual report |
|
|
| Semi-annual report |
|
|
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.